Inhibrx Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INXB research report →
About the company
Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity, primarily focused on developing advanced biologic treatments for critical, life-threatening medical conditions. Key assets within its development pipeline include: INBRX-109, a tetravalent investigational therapy, is progressing through Phase 2 clinical trials.
- CEO
- Mark Paul Lappe
- IPO
- 2018
- Employees
- 166
- HQ
- La Jolla, CA, US
Price Chart
- Market Cap
- $225.87M
- P/E
- -11.63
- P/S
- 1101.24
- P/B
- -72.30
- EV/EBITDA
- -10.90
- Div Yield
- 0.00%
- Gross Margin
- -80.38%
- Op Margin
- -9465.46%
- Net Margin
- -10014.23%
- ROE
- -563.89%
- ROIC
- -76.97%
- 52W High
- $18.95
- 52W Low
- $12.95
- 50D MA
- $16.45
- 200D MA
- $16.45
- Beta
- 2.88
- Avg Volume
- 440.58K
Get TickerSpark's AI analysis on INXB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 24, 24 | Inhibrx, Inc. | other | 0 |
Our INXB coverage
Recent articles, reports, and earnings notes.
No research on INXB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INXB report →Similar companies
Peers in the same neighborhood.